# Reducing Vertical Transmission of Hepatitis B in Africa

> **NCT04704024** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **University of Alabama at Birmingham** · enrollment: 450 (estimated)

## Conditions studied

- Hepatitis B Infection

## Interventions

- **DRUG:** Tenofovir Disoproxil Fumarate
- **DRUG:** Lamivudine Oral Solution

## Key facts

- **NCT ID:** NCT04704024
- **Lead sponsor:** University of Alabama at Birmingham
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-09-03
- **Primary completion:** 2026-08-01
- **Final completion:** 2026-12-31
- **Target enrollment:** 450 (ESTIMATED)
- **Last updated:** 2025-10-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04704024

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04704024, "Reducing Vertical Transmission of Hepatitis B in Africa". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT04704024. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*